Related references
Note: Only part of the references are listed.Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study
C. Kent Osborne et al.
CLINICAL CANCER RESEARCH (2011)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2009)
Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC
Pamela Munster et al.
CLINICAL CANCER RESEARCH (2009)
Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor-Positive, Aromatase Inhibitor-Resistant Advanced Breast Cancer A Phase 2 Randomized Study
Matthew J. Ellis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability
Douglas C. Marchion et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Histone deacetylase inhibitor SAHA induces ERα degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling
Xin Yi et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling
Elona Bicaku et al.
CANCER RESEARCH (2008)
A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study
Thehang H. Luu et al.
CLINICAL CANCER RESEARCH (2008)
Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells
Leslie Hodges-Gallagher et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-α levels and transcriptional activity:: A result of hyperacetylation and inhibition of chaperone function of heat shock protein 90
Warren Fiskus et al.
CLINICAL CANCER RESEARCH (2007)
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors:: A clinical and translational study
Pamela Muenster et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation
Qun Zhou et al.
CANCER BIOLOGY & THERAPY (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
Valproic acid-induced gene expression through production of reactive oxygen species
Yumiko Kawai et al.
CANCER RESEARCH (2006)
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: Tamoxifen-bound reactivated ER recruits distinctive corepressor complexes
D Sharma et al.
CANCER RESEARCH (2006)
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
OA O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer
S Saji et al.
ONCOGENE (2005)
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
WK Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen
ER Jang et al.
ONCOGENE (2004)
Histone deacetylase inhibitor trichostatin a represses estrogen receptor α-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines
JP Alao et al.
CLINICAL CANCER RESEARCH (2004)
Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor α
H Kawai et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
